Claudia Haferlach mainly focuses on Internal medicine, Leukemia, Myeloid leukemia, Myeloid and Cancer research. Her studies deal with areas such as Gastroenterology, Immunology, Oncology and Cytogenetics as well as Internal medicine. Her work carried out in the field of Leukemia brings together such families of science as Myeloproliferative neoplasm, Mutation, Gene mutation, Neuroblastoma RAS viral oncogene homolog and Survival analysis.
Her Myeloid leukemia study integrates concerns from other disciplines, such as Chronic myelogenous leukemia, Surgery and NPM1. Her study ties her expertise on Myelodysplastic syndromes together with the subject of Myeloid. Her work deals with themes such as Acute lymphocytic leukemia and B cell, which intersect with Cancer research.
Claudia Haferlach focuses on Leukemia, Internal medicine, Oncology, Myeloid leukemia and Genetics. Her Leukemia study incorporates themes from Myeloid, Cancer research, NPM1 and Cytogenetics. Her research in Cancer research intersects with topics in Cancer and Fusion gene.
Her Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology, Karyotype and Pathology. Her Oncology research includes themes of Transplantation, Bioinformatics, Minimal residual disease, Chronic lymphocytic leukemia and Cohort. Claudia Haferlach works in the field of Myeloid leukemia, namely Imatinib.
Her scientific interests lie mostly in Leukemia, Cancer research, Internal medicine, Myeloid leukemia and Myeloid. Her Leukemia study combines topics in areas such as Mutation, Young adult, NPM1 and Chromosome abnormality. Her Cancer research research is multidisciplinary, relying on both RNA, Transcription factor and Gene expression, DNA methylation.
The Internal medicine study combines topics in areas such as Gastroenterology, Oncology and Karyotype. Her biological study spans a wide range of topics, including Exome sequencing and Myelogenous. Her Myeloid research includes elements of MECOM and Minimal residual disease.
Internal medicine, Leukemia, Myeloid leukemia, Myeloid and Oncology are her primary areas of study. The various areas that Claudia Haferlach examines in her Internal medicine study include Gastroenterology and Chromosome 7. Her Leukemia research is multidisciplinary, incorporating perspectives in Young adult, CCAAT/enhancer binding protein alpha and Chimera.
Myeloid leukemia is a subfield of Cancer research that Claudia Haferlach investigates. Her Myeloid study combines topics from a wide range of disciplines, such as Genetics, NPM1, PDGFRB and Pathology. Claudia Haferlach has included themes like Survival rate, Treatment strategy, Imatinib and Cancer in her Oncology study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Frequent pathway mutations of splicing machinery in myelodysplasia
Kenichi Yoshida;Masashi Sanada;Yuichi Shiraishi;Daniel Nowak.
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
T Haferlach;Y Nagata;V Grossmann;Y Okuno.
BRAF mutations in hairy-cell leukemia
Enrico Tiacci;Vladimir Trifonov;Gianluca Schiavoni;Antony Holmes.
The New England Journal of Medicine (2011)
Deregulated expression of cytokine receptor gene, CRLF2 , is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia
Lisa J. Russell;Melania Capasso;Inga Vater;Takashi Akasaka.
Landscape Of Genetic Lesions In 944 Patients With Myelodysplastic Syndromes
Yasunobu Nagata;Vera Grossmann;Yusuke Okuno;Ulrike Bacher.
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).
B. Hanfstein;M. C. Müller;R. Hehlmann;P. Erben.
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients
Ulrike Bacher;Claudia Haferlach;Wolfgang Kern;Torsten Haferlach.
Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV H status and immunophenotyping
C Haferlach;F Dicker;S Schnittger;W Kern.
Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
Rüdiger Hehlmann;Michael Lauseker;Susanne Jung-Munkwitz;Armin Leitner.
Journal of Clinical Oncology (2011)
Minimal residual disease levels assessed by NPM1 mutation–specific RQ-PCR provide important prognostic information in AML
Susanne Schnittger;Wolfgang Kern;Claudia Tschulik;Tamara Weiss.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: